Weight loss-focused lifestyle interventions significantly impacted bone health biomarkers among patients with T2D.

The EULAR released a 2025 update to the 2018 recommendations for physical activity among individuals with IA or OA, with an emphasis on reducing sedentary behavior.

The United States Food and Drug Administration recently approved Sotyktu TM (deucravacitinib) for the treatment of active psoriatic arthritis (PsA) among adults. Which of the statements below about ...

Use of IL-17 inhibitors is effective and safe for the treatment of PsO involving difficult-to-treat anatomical sites.

Combination treatment of CBT for insomnia plus medication is recommended over medication alone for adults with chronic insomnia disorder.

Treatment with the ustekinumab biosimilar AVT04 was safe and effective for patients with plaque PsO, regardless of previous use of the reference product.

The US Food and Drug Administration is moving to speed drug development and review by launching real-time clinical trials.

US adults show strong interest in brain health, but very few report knowing a lot about ways to maintain a healthy brain.

Adults with AD, HS, and PsO have higher rates of psychiatric evaluation, psychotherapy, and psychiatric treatment compared with matched control patients.

Rheumatology providers reported multiple barriers to providing routine cognitive screening and neuropsychological evaluation in patients with cSLE.

For older adults, deterioration in cognitive function is seen prior to cardiovascular disease events, according to results of a recent study.

Higher intake of legumes and soy products is associated with fewer chronic obstructive pulmonary disease symptoms among former smokers.